Extended Data Fig. 8: Murine pharmacokinetic (PK) parameters for JNJ-6640.
From: Targeting de novo purine biosynthesis for tuberculosis treatment
a, Results are expressed as the mean ± SD. n = 3 animals were dosed for the IV and PO arms and n = 3 animals by alternating sampling (from a total of 6 dosed) for SC arms (LAI), alternating sampling per time point was performed to limit the number of times blood was collected per animal, therefore we were unable to calculate error for these treatments. CL: clearance; Cmax = maximum concentration reached; t1/2: half-life; AUC: area under the curve; MRT: Mean residence time; F: bioavailability; Vss: volume of distribution; Vz: terminal elimination phase. b, Comparison of total plasma concentration profiles of JNJ-6640 administered as IV (1 mg kg−1), PO (5 mg kg−1 and 50 mg kg−1) or SC (1500 mg kg−1; LAI). n = 3 mice ± SD (IV and PO) or n = 3 mice (from a total of 6) for LAI PK studies, alternating sampling in 3 mice per time point. c, PK profiles following one or two doses of 1500 mg kg−1 JNJ-6640 LAI over 4 weeks. n = 3 mice (from a total of 6) alternating sampling in 3 mice per time point. Data shown are mean ± SD.
